• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2003 Fiscal Year Final Research Report Summary

Study on the mechanism by which apolipoprotein(apo) E2 promotes diabetic nephropathy

Research Project

Project/Area Number 14571112
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Metabolomics
Research InstitutionKawasaki Medical School

Principal Investigator

ETO Masaaki  Kawasaki Medical School, Department of Medicine, Associate professor, 医学部, 助教授 (90133818)

Co-Investigator(Kenkyū-buntansha) SAITO Mieko  Kawasaki Medical School, Department of Medicine, Assistant professor, 医学部, 講師 (60319952)
Project Period (FY) 2002 – 2003
Keywordsdiabetic nephropathy / apo E2 / apolipoprotein / apo E genotype / remnant lipoproteins / TGF-b / mesangial cells / PKC activity
Research Abstract

Background and Aim : In 1994 we first demonstrated that the apolipoprotein(apo) E ε2 allele is associated with the progression of diabetic nephropathy. Apo E2 is well known to contribute to high plasma levels of remnant lipoproteins. The aim of the present study is to further investigate the association between apo E genetic polymorphism, remnant lipoproteins and diabetic nephropathy.
Subjects and Methods : Type 2 diabetic patients who had a diabetes duration over 10 years were divided into the 3 apo E groups ; apo E2(n=22),E3/3(n=102) and E4(n=34). Plasma levels of lipids and remnant lipoproteins were measured. Histologic studies were performed using renal biopsy specimens in apo E2 patient. The effects of apo E2-IDL(remnant lipoproteins) on cultured human mesangial cells were studied.
Results : The frequency of overt nephropathy was significantly higher in apo E2 diabetic patients(59.1%) than in apo E3/3(34.3%) or apo E4 patients(8.8%), and there was also a significant difference in the frequency of overt nephropathy between apo E3/3 and E4 groups. Plasma levels of triglyceride and remnant-like lipoprotein particles(RLP)-chol and were significantly higher in apo E2 patients, and significantly lower in apo E4 patients than in apo E3/3 patients. Logistical regression analysis showed that odds ratios of high plasma remnant(RLP-C≧5.2mg/dl) for the presence of overt nephropathy were 3.614(p=0.0208). Histological renal change of apo E2 patient was almost identical to diabetic nephropathy. Immunohistochemically, apo E and apo B were stained in glomerulus of apo E2 patient. Apo E2-IDL stimulated significantly PKC activity, TGF-b synthesis, and type IV collagen and fibronectin synthesis in mesangial cells sa compared with apo E3/3-IDL.
Conclusion : Remnant lipoproteins may have an important role in the progression of diabetic nephropathy.

  • Research Products

    (10 results)

All Other

All Publications (10 results)

  • [Publications] Eto M, Saito M, Okada M, Kume Y, Kawasaki F, Matsuda M, Yoneda M, Matsuki M, Takigami S, Kaku K: "Apolipoprotein E genetic polymorphism, remnant lipoproteins and nephropathy in Type 2 diabetic patients"Am J Kidney Dis. 40. 243-251 (2002)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Saito M, Eto M, Kaku K: "Remnant-like lipoprotein particles (RLP) in type 2 diabetic patients with apolipoprotein E3/3 genotype and with apo E2 genotypes"Metabolism. 51. 964-969 (2002)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Eto M, Saito M, Nakata H, Iwashima Y, Watanabe K, Makino I, Kaku K: "Type III hyperlipoproteinemia with apolipoprotein E2/2 genotype in Japan"Clinical Genetics. 61. 416-422 (2002)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Hamano M, Saito M, Eto M et al.: "Serum amyloid A (SAA), C-reactive protein (CRP) and remnant-like lipoprotein particls (RLP)-cholesterol in type 2 diabetic patients with coronary heart disease"Ann Clin Biochem. 41. 125-129 (2004)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Saito M, Eto M, Nitta H, et al.: "Effect of apolipoprotein E4 allele on plasma LDL-cholesterol response to diet therapy in type 2 diabetic patients"Diabetes Care. (In press).

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Eto M, Saito M, Okada M, Kume Y, Kawasaki F, Matsuda M, Yoneda M, Matsuki M, Takigami S, Kaku K.: "Apolipoprotein E genetic polymorphism, remanat lipoproteins and nephropathy in type 2 diabetic patients."Am J Kidney Dis. 40. 243-251 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Saito M, Eto M, Kaku K.: "Remant-like lipoprotein particles(RLP) in type 2 diabetic patients with apolipoprotein E3/3 genotype and with apolipoprotein E2 genotypes."Metabolism. 51. 964-969 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Eto M, Saito M, Nakata H, Iwashima Y, Watanabe K, IkodaA, Kaku K.: "Type III hyperlipoproteinemia with apolipoprotein E2/2 genotype in Japan."Clinical Genetics. 61. 416-422 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Hamano M, Saito M, Eto M, Nishimatsu S, Matsuda M, Matsuki M, Suda H, Yamamoto S, Kaku K.: "Serum amylod A(SAA), C-reactive protein(CRP) and remnant-like lipoprotein particles(RLP)-cholesterol in type 2 diabetic patients with coronary heart disease."Ann Clin Biochem. 41. 125-129 (2004)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Saito M, Eto M, Nitta H, Kanda Y, Shigeto M, Nakayama K, Tawaramoto K, Kawasaki F, Kamei S, Kohara K, Matsuda M, Matsuki M, Kaku K.: "Effect of apolipoprotein E4 allele on plasma LDL cholesterol response to diet therapy in type 2 diabetic patients."Diabetes Care. (in press).

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 2005-04-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi